Description
Patients with advanced NSCLC have traditionally been treated with platinum-based two-drug combination chemotherapy in patients with an appropriate performance status. An increase in understanding about the pathogenesis and molecular biology of NSCLC has enabled the more recent development of targeted agents that have changed management paradigms.